Attorney's Docket No.: 01997-273003 / MIT Case 7772 DI

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 2 5 2002

Serial No.: 09/832,959

pplicant: Moungi G. Bawendi et al.

Art Unit : 1641

Examiner: Christopher L. Chin

TECH CENTER 1600/2900

Filed

April 12, 2001

Title : BIOLOGICAL APPLICATIONS OF QUANTUM DOTS

Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the action mailed September 23, 2002 ("Office Action"), Applicants elect the invention of Group II (claims 69-77) drawn to a method of detecting biological moieties. The election is made with traverse.

Applicants respectfully request that the invention of Group I (claims 46-47, 49-68 and 78) drawn to a method of detecting interaction between a composition and a biological moiety be combined with the invention of Group II. The Examiner indicates at page 3 of the Office Action that the "inventions are not disclosed as capable of use together because they are directed to two different method [sic] with different method steps and use different reagent [sic] and thus have different modes of operation to produce different effects." Applicants respectfully disagree. Both independent claim 46 (Group I) and independent claim 69 (Group II) relate to a method of using compound and a semiconductor nanocrystal associated with the compound. The reagent is not different. Both claims include allowing a sample to interact with the composition and monitoring or detecting an interaction, which are similar method steps. Thus, the claims of Group I and the claims of Group II should be searched together. Applicants respectfully request that Group II and Group I be combined and examined together.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 10-23-02

Harold H. Fox

Reg. No. 41,498

Fish & Richardson P.C. 1425 K Street, N.W.

Washington, DC 20005-3500 Telephone: (202) 783-5070

40125623.doc

Facsimile: (202) 783-2331